BROOKLYN PARK, Minnesota — March 5, 2026
Airiver Medical, a clinical-stage medical technology company focused on innovative respiratory therapies, has announced that the U.S. Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval for a pivotal clinical trial evaluating its ESSpand Sinus Drug Coated Balloon (DCB) in patients suffering from Chronic Rhinosinusitis (CRS). The IDE authorization enables the company to initiate a nationwide clinical study enrolling up to 300 patients, aimed at evaluating the safety and effectiveness of the technology when used during endoscopic sinus surgery. The innovative device combines mechanical balloon dilation with localized drug delivery, designed to maintain sinus passage patency and prevent scarring after surgical intervention, potentially offering long-term symptom relief for patients affected by chronic sinus inflammation.
FDA IDE Approval Enables Nationwide Pivotal Trial
The IDE clearance from the FDA represents a critical regulatory milestone that allows Airiver Medical to begin a large-scale pivotal clinical investigation across multiple medical centers in the United States. The study will enroll up to 300 patients diagnosed with chronic rhinosinusitis, including individuals both with and without nasal polyps, to determine the safety and effectiveness of the ESSpand Drug Coated Balloon technology.
Researchers will evaluate whether the device can improve long-term sinus drainage and reduce symptom recurrence following endoscopic sinus surgery (ESS). Key clinical endpoints will include symptom relief, maintenance of sinus opening patency, and prevention of post-surgical tissue scarring or narrowing of sinus pathways.
The results of the trial are expected to generate the clinical evidence necessary for Airiver Medical’s future regulatory submission to the FDA, potentially enabling the commercialization of the device in the United States. If successful, the ESSpand DCB could represent a new minimally invasive treatment option for patients who continue to experience symptoms despite standard medical therapy or surgical intervention.
Advertisement
Drug-Coated Balloon Technology Combines Dilation and Targeted Therapy
The ESSpand Sinus Drug Coated Balloon is designed to address one of the key challenges in sinus surgery: the recurrence of blocked sinus drainage pathways caused by inflammation and scar tissue formation.
During treatment, the device is inserted into narrowed sinus passages and gently inflated to expand the blocked drainage pathways, restoring airflow and normal sinus drainage. At the same time, the balloon delivers a thin layer of paclitaxel directly to the surrounding sinus tissue. Paclitaxel is known for its anti-proliferative properties, which may help reduce tissue inflammation, inhibit scar formation, and prevent the re-narrowing of the treated sinus channels.
By combining mechanical dilation with localized drug therapy, the ESSpand DCB aims to deliver more durable treatment outcomes than balloon dilation procedures alone. This integrated approach could help patients achieve long-lasting symptom relief while reducing the likelihood of repeat surgical interventions.
Currently, the ESSpand DCB remains an investigational medical device and has not yet received FDA marketing authorization, meaning it is still under clinical evaluation and not available for commercial use in the United States.
Chronic Rhinosinusitis Represents a Major Global Health Burden
Chronic rhinosinusitis is one of the most common long-term respiratory diseases, affecting millions of people worldwide. The condition is characterized by persistent inflammation of the nasal passages and paranasal sinuses lasting at least three months despite treatment.
Patients suffering from CRS often experience nasal congestion, facial pressure, headaches, reduced sense of smell, fatigue, and breathing difficulties. While medications such as corticosteroids or antibiotics can provide temporary relief, many patients eventually require endoscopic sinus surgery to reopen blocked sinus passages.
However, even after surgery, symptoms frequently recur because of tissue scarring and narrowing of the sinus drainage pathways, forcing some patients to undergo additional procedures. Innovative technologies capable of maintaining long-term sinus patency and preventing tissue regrowth are therefore considered an important area of advancement in otolaryngology and respiratory medicine.
Through the development of its drug-coated balloon technology, Airiver Medical aims to improve treatment outcomes for chronic rhinosinusitis patients by providing sustained airway patency, reducing inflammation, and minimizing the need for repeat surgeries.
As healthcare systems continue to prioritize minimally invasive therapies and improved patient outcomes, technologies such as the ESSpand Drug Coated Balloon may play a critical role in transforming the treatment landscape for chronic sinus disease.
z
Source: Airiver Medical press release
